These findings suggest that NEP1 reverses PIWIL2-driven oncogenic changes, including c-myc nuclear accumulation and chemoresistance, and synergistically enhances 5-FU efficacy, supporting its potential as a targeted cancer therapy. The gene discussed is PIWIL2; the disease is cancer.